A new psychedelics fund launches in the US

Leading U.S.-Based Psychedelic Healthcare VC Fund Launches with $35 Million Raised to Tackle the Growing Global Mental Health Crisis

Another $35 million was just invested into US psychedelics companies.

Palo Santo, a US venture capital investment fund, invested $35 million into psychedelic research, exceeding its $30 million goal. The portfolio consists of 20 early-stage psychedelic companies with high growth potential including Atai Life Sciences, Reset Pharma, Field Trip Health, Tactogen, Eleusis, Bexson Biomedical, and more. Palo Santo’s team of investors will actively support each company in the portfolio by connecting founders, advisers, and industry leaders through their vast network in the healthcare space.